Ogivri Intravenous and Skyrizi topical

• Generic Name: trastuzumab
• Dosage Forms: injection
• Other Brand Names: Herceptin, Kanjinti, Ogivri

Trastuzumab-dkst injection is used alone or together with other cancer medicines (eg, carboplatin, cyclophosphamide, docetaxel, doxorubicin, paclitaxel) to treat HER2-overexpressing new or metastatic (cancer that has spread) breast cancer.

Trastuzumab-dkst injection is also used in combination with cisplatin and capecitabine or 5-fluorouracil to treat HER2-overexpressing metastatic (cancer that has spread) stomach and gastroesophageal (stomach and esophagus) cancer.

Trastuzumab-dkst prevents the growth of some tumors that produce extra amounts of a certain substance known as the HER2 protein. It should only be used in patients whose tumors have been shown to produce extra amounts of this protein (HER2 overexpression).

Trastuzumab-dkst is a monoclonal antibody. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal body cells may also be affected by trastuzumab-dkst, other effects will also occur. Some of these may be serious and must be reported to your doctor. Other effects, such as a skin rash, may not be serious but may cause concern. Some effects do not occur until months or years after the medicine is used.

This medicine is to be given only by or under the immediate supervision of your doctor.

• Generic Name: risankizumab
• Dosage Forms: n.a.
• Other Brand Names: Skyrizi

Risankizumab-rzaa is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.